As pointed out, CXCL12 and its ligand CXCRA can have a pathologic role in different stages of MM and patient drug resistance, so disrupting the CXCL12-CXCR4 axis might be a therapeutic opportunity [39]. This evidence concerns the gene CXCL12 and Miyoshi myopathy.